Skip to main content
Top
Published in: Clinical Research in Cardiology 6/2017

Open Access 01-06-2017 | Original Paper

Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry

Authors: Marco Proietti, K. E. Juhani Airaksinen, Andrea Rubboli, Axel Schlitt, Tuomas Kiviniemi, Pasi P. Karjalainen, Gregory Y. H. Lip, On behalf of the AFCAS Study Group

Published in: Clinical Research in Cardiology | Issue 6/2017

Login to get access

Abstract

Background

In patients with atrial fibrillation (AF), quality of oral anticoagulation control as well as impaired renal function are associated with adverse outcomes. Our objective was to analyze if there was a synergistic impact of these factors in determining adverse outcomes in AF patients undergoing percutaneous coronary intervention and stent (PCI-S).

Methods

Post-hoc analysis from the Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry. Poor oral anticoagulation control was defined as time in therapeutic range (TTR) <65%, while impaired renal function as creatinine clearance (CrCl) <60 ml/min.

Results

Of the whole cohort, 448 were eligible for this post-hoc analysis. Of these, 27.9% had TTR <65%only (Group I), 19.2% had CrCl <60 ml/min only (Group II), while 13.8% had both conditions (Group III). At follow-up, patients in Group III had a higher rate of major adverse cardiovascular and cerebrovascular events (MACCE) (p = 0.007), while patients in Groups I and III had higher rates of major bleeding. Kaplan–Meier analyses showed that patients in Group III had higher risk for MACCE (LogRank: 14.406, p = 0.003), while Group I and Group III patients had higher risk for major bleeding (LogRank: 12.290, p = 0.006). On Cox regression, presence of both conditions independently increased MACCE risk (p = 0.001), while TTR <65% alone and the presence of both conditions were independently associated with major bleeding (p = 0.004 and p = 0.028, respectively).

Conclusions

There was a synergic impact of oral anticoagulation control and renal function in determining major adverse events in AF patients undergoing PCI-S. Use of poor anticoagulation control and impaired renal function in combination would help identify AF patients undergoing PCI-S at risk for MACCE and/or major bleeding.
Appendix
Available only for authorised users
Literature
2.
go back to reference Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA (2016) Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ 354:i4482CrossRefPubMed Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA (2016) Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ 354:i4482CrossRefPubMed
3.
go back to reference Proietti M, Lip GYH (2016) Atrial fibrillation and stroke: making sense of recent observations on anticoagulation. Cardiol Clin 34:317–328CrossRefPubMed Proietti M, Lip GYH (2016) Atrial fibrillation and stroke: making sense of recent observations on anticoagulation. Cardiol Clin 34:317–328CrossRefPubMed
4.
go back to reference Freedman B, Potpara TS, Lip GYH (2016) Stroke prevention in atrial fibrillation. The Lancet 388:806–817CrossRef Freedman B, Potpara TS, Lip GYH (2016) Stroke prevention in atrial fibrillation. The Lancet 388:806–817CrossRef
5.
go back to reference Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ et al (2015) Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the gloria-af registry, phase II. Am J Med 128:1306–1313.e1CrossRefPubMed Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ et al (2015) Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the gloria-af registry, phase II. Am J Med 128:1306–1313.e1CrossRefPubMed
7.
go back to reference Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P et al (2008) Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 1:84–91CrossRefPubMed Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P et al (2008) Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 1:84–91CrossRefPubMed
8.
go back to reference Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa T-P (2011) Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 106:968–977CrossRefPubMed Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa T-P (2011) Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 106:968–977CrossRefPubMed
9.
go back to reference Lau YC, Proietti M, Guiducci E, Blann AD, Lip GYH (2016) Atrial fibrillation and thromboembolism in patients with chronic kidney disease. J Am Coll Cardiol 68:1452–1464CrossRefPubMed Lau YC, Proietti M, Guiducci E, Blann AD, Lip GYH (2016) Atrial fibrillation and thromboembolism in patients with chronic kidney disease. J Am Coll Cardiol 68:1452–1464CrossRefPubMed
11.
go back to reference Lip GYH, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM et al (2014) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on. Eur Heart J 35:3155–3179CrossRefPubMed Lip GYH, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM et al (2014) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on. Eur Heart J 35:3155–3179CrossRefPubMed
12.
go back to reference Schlitt A, Rubboli A, Lip GYH, Lahtela H, Valencia J, Karjalainen PP et al (2013) The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the atrial fibrillation undergoing coronary artery stenting study. Catheter Cardiovasc Interv 82:E864–E870CrossRefPubMed Schlitt A, Rubboli A, Lip GYH, Lahtela H, Valencia J, Karjalainen PP et al (2013) The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the atrial fibrillation undergoing coronary artery stenting study. Catheter Cardiovasc Interv 82:E864–E870CrossRefPubMed
13.
go back to reference Rubboli A, Schlitt A, Kiviniemi T, Biancari F, Karjalainen PP, Valencia J et al (2014) One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. Clin Cardiol 37:357–364CrossRefPubMed Rubboli A, Schlitt A, Kiviniemi T, Biancari F, Karjalainen PP, Valencia J et al (2014) One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. Clin Cardiol 37:357–364CrossRefPubMed
14.
go back to reference Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272CrossRefPubMed Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272CrossRefPubMed
15.
go back to reference Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236–239PubMed Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236–239PubMed
16.
go back to reference Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG et al (2008) Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118:2029–2037CrossRefPubMed Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG et al (2008) Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118:2029–2037CrossRefPubMed
17.
go back to reference Gallego P, Roldan V, Marín F, Romera M, Valdés M, Vicente V et al (2013) Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 110:1189–1198CrossRefPubMed Gallego P, Roldan V, Marín F, Romera M, Valdés M, Vicente V et al (2013) Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 110:1189–1198CrossRefPubMed
18.
go back to reference Bolton K et al (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1–S266 Bolton K et al (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1–S266
19.
go back to reference Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M et al (2007) Universal definition of myocardial infarction. Circulation 116:2634–2653CrossRefPubMed Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M et al (2007) Universal definition of myocardial infarction. Circulation 116:2634–2653CrossRefPubMed
20.
go back to reference Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A et al (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351CrossRefPubMed Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A et al (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351CrossRefPubMed
21.
go back to reference Lau YC, Hardy LJ, Philippou H, Blann AD, Lip GYH (2016) Altered fibrin clot structure in patients with atrial fibrillation and worsening renal function. Thromb Haemost 116:408–409CrossRefPubMed Lau YC, Hardy LJ, Philippou H, Blann AD, Lip GYH (2016) Altered fibrin clot structure in patients with atrial fibrillation and worsening renal function. Thromb Haemost 116:408–409CrossRefPubMed
22.
go back to reference Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L et al (2009) Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 119:1363–1369CrossRefPubMedPubMedCentral Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L et al (2009) Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 119:1363–1369CrossRefPubMedPubMedCentral
23.
go back to reference Friberg L, Rosenqvist M, Lip GYH (2012) Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 33:1500–1510CrossRefPubMed Friberg L, Rosenqvist M, Lip GYH (2012) Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 33:1500–1510CrossRefPubMed
24.
go back to reference Olesen JB, Lip GYH, Kamper A-L, Hommel K, Køber L, Lane DA et al (2012) Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367:625–635CrossRefPubMed Olesen JB, Lip GYH, Kamper A-L, Hommel K, Køber L, Lane DA et al (2012) Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367:625–635CrossRefPubMed
25.
go back to reference Bonde AN, Lip GYHH, Kamper A-L, Hansen PR, Lamberts M, Hommel K et al (2014) Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease. J Am Coll Cardiol 64:2471–2482 Bonde AN, Lip GYHH, Kamper A-L, Hansen PR, Lamberts M, Hommel K et al (2014) Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease. J Am Coll Cardiol 64:2471–2482
26.
go back to reference Boriani G, Laroche C, Diemberger I, Popescu MI, Rasmussen LH, Petrescu L et al (2016) Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. Sci Rep 6:30271CrossRefPubMedPubMedCentral Boriani G, Laroche C, Diemberger I, Popescu MI, Rasmussen LH, Petrescu L et al (2016) Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. Sci Rep 6:30271CrossRefPubMedPubMedCentral
27.
go back to reference Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS et al (2013) Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 127:224–232CrossRefPubMed Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS et al (2013) Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 127:224–232CrossRefPubMed
28.
go back to reference Roldán V, Marín F, Manzano-Fernandez S, Fernández H, Gallego P, Valdés M et al (2013) Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 109:956–960CrossRefPubMed Roldán V, Marín F, Manzano-Fernandez S, Fernández H, Gallego P, Valdés M et al (2013) Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 109:956–960CrossRefPubMed
29.
go back to reference Banerjee A, Fauchier L, Vourc’h P, Andres CR, Taillandier S, Halimi JM et al (2013) Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol 61:2079–2087CrossRefPubMed Banerjee A, Fauchier L, Vourc’h P, Andres CR, Taillandier S, Halimi JM et al (2013) Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol 61:2079–2087CrossRefPubMed
30.
go back to reference Providência R, Marijon E, Boveda S, Barra S, Narayanan K, Le Heuzey J-Y et al (2014) Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol 114:646–653CrossRefPubMed Providência R, Marijon E, Boveda S, Barra S, Narayanan K, Le Heuzey J-Y et al (2014) Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol 114:646–653CrossRefPubMed
31.
go back to reference Apostolakis S, Guo Y, Lane DA, Buller H, Lip GYH (2013) Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J 34:3572–3579CrossRefPubMed Apostolakis S, Guo Y, Lane DA, Buller H, Lip GYH (2013) Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J 34:3572–3579CrossRefPubMed
32.
go back to reference Banerjee A, Fauchier L, Vourc’h P, Andres CR, Taillandier S, Halimi JM et al (2014) A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 145:1370–1382CrossRefPubMed Banerjee A, Fauchier L, Vourc’h P, Andres CR, Taillandier S, Halimi JM et al (2014) A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 145:1370–1382CrossRefPubMed
33.
go back to reference De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F et al (2013) Vitamin K antagonists in heart disease: current status and perspectives (section III). Thromb Haemost 110:1087–1107CrossRefPubMed De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F et al (2013) Vitamin K antagonists in heart disease: current status and perspectives (section III). Thromb Haemost 110:1087–1107CrossRefPubMed
34.
go back to reference Chan EW, Lau WCY, Siu CW, Lip GYH, Leung WK, Anand S et al (2016) Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: a population-wide cohort study. Hear Rhythm 13:1581–1588CrossRef Chan EW, Lau WCY, Siu CW, Lip GYH, Leung WK, Anand S et al (2016) Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: a population-wide cohort study. Hear Rhythm 13:1581–1588CrossRef
35.
go back to reference Senoo K, Lip GYH (2016) Female sex, time in therapeutic range, and clinical outcomes in atrial fibrillation patients taking warfarin. Stroke 47:1665–1668CrossRefPubMed Senoo K, Lip GYH (2016) Female sex, time in therapeutic range, and clinical outcomes in atrial fibrillation patients taking warfarin. Stroke 47:1665–1668CrossRefPubMed
36.
go back to reference Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P et al (2015) Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry. Am Heart J 170:141–148.e1CrossRefPubMed Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P et al (2015) Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry. Am Heart J 170:141–148.e1CrossRefPubMed
37.
go back to reference Best PJM, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR et al (2002) The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 39:1113–1119CrossRefPubMed Best PJM, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR et al (2002) The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 39:1113–1119CrossRefPubMed
38.
go back to reference Maree AO, Margey RJ, Selzer F, Bajrangee A, Jneid H, Marroquin OC et al (2016) Renal insufficiency, bleeding and prescription of discharge medication in patients undergoing percutaneous coronary intervention in the national heart, lung, and blood institute (NHLBI) dynamic registry. Cardiovasc Revasc Med 17:302–327CrossRefPubMed Maree AO, Margey RJ, Selzer F, Bajrangee A, Jneid H, Marroquin OC et al (2016) Renal insufficiency, bleeding and prescription of discharge medication in patients undergoing percutaneous coronary intervention in the national heart, lung, and blood institute (NHLBI) dynamic registry. Cardiovasc Revasc Med 17:302–327CrossRefPubMed
39.
go back to reference Lahtela HM, Kiviniemi TO, Puurunen MK, Schlitt A, Rubboli A, Ylitalo A et al (2015) Renal impairment and prognosis of patients with atrial fibrillation undergoing coronary intervention—The AFCAS trial. PLoS One 10:e0128492CrossRefPubMedPubMedCentral Lahtela HM, Kiviniemi TO, Puurunen MK, Schlitt A, Rubboli A, Ylitalo A et al (2015) Renal impairment and prognosis of patients with atrial fibrillation undergoing coronary intervention—The AFCAS trial. PLoS One 10:e0128492CrossRefPubMedPubMedCentral
Metadata
Title
Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry
Authors
Marco Proietti
K. E. Juhani Airaksinen
Andrea Rubboli
Axel Schlitt
Tuomas Kiviniemi
Pasi P. Karjalainen
Gregory Y. H. Lip
On behalf of the AFCAS Study Group
Publication date
01-06-2017
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 6/2017
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-016-1071-0

Other articles of this Issue 6/2017

Clinical Research in Cardiology 6/2017 Go to the issue